Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MECP2 | P51608 | 1/20 | 0.40 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.40 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.40 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.40 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284289 | 0.80 | PDE4B (0.58) | ADORA2AADORA1MEN1KMT2ARAB9A | |
| SCHEMBL25195068 | 0.76 | ACVR1 (0.65) | ADORA2AADORA1CDK5DYRK1ACDK5R1 | |
| SCHEMBL22412139 | 0.75 | CDK2 (0.54) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL29549332 | 0.75 | ADORA2A (0.43) | ADORA2AADORA1MEN1KMT2ARAB9A | |
| SCHEMBL22828480 | 0.75 | ADORA2A (0.43) | ADORA2AADORA1MEN1KMT2ARAB9A | |
| SCHEMBL14606095 | 0.75 | PAK1 (0.60) | CDK5DYRK1ACDK5R1KDRMEN1 | |
| SCHEMBL30147226 | 0.75 | PAK1 (0.60) | CDK5DYRK1ACDK5R1KDRMEN1 | |
| SCHEMBL25214598 | 0.75 | ACVR1 (0.45) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL19867253 | 0.73 | HTT (0.45) | ADORA2AADORA1MEN1KMT2ANPC1 | |
| SCHEMBL1284185 | 0.73 | CYP2A6 (0.42) | CCNA2CDK2CCNA1CDK5DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-10894795-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200339593-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10676482-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190352310-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2019-11-21 | — | — | US | disclosed |
| US-10336770-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9725461-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-23 | — | — | US | disclosed |
| EP-2385832-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-10336770-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | ADORA2A 1944/4885ADORA1 3925/4885CCNA2 2597/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-10894795-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | ADORA2A 1944/4885ADORA1 3925/4885CCNA2 2597/4885 |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1944/4885ADORA1 3925/4885CCNA2 2597/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-20200339593-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1944/4885ADORA1 3925/4885CCNA2 2597/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1944/4885ADORA1 3925/4885CCNA2 2597/4885 |
| US-10676482-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | ADORA2A 4566/4885ADORA1 4731/4885CCNA2 741/4885 |
| US-20190352310-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ADORA2A 1928/4885ADORA1 3923/4885CCNA2 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.